A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

  • STATUS
    Recruiting
  • End date
    Aug 31, 2022
  • participants needed
    205
  • sponsor
    AbbVie
Updated on 27 October 2021
cancer
myeloid leukemia
hematologic malignancy
lymphoma
hodgkin's disease
measurable disease
leukemia
bone marrow procedure
KRAS
bevacizumab
primary cancer
solid tumour
solid tumor
solid neoplasm

Summary

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies.

Details
Condition Hematologic Malignancy, Blood disorder, Cancer, Cancer/Tumors, Solid Tumors, Advanced Solid Tumors, Ewing's Family Tumors, Cancer (Pediatric), Advanced Solid Tumors Cancer, Blood Cancer, Neoplasms, Hematologic Cancer, Hematological Disorders, Hematologic Neoplasms, primary cancer, primary malignant neoplasm, malignancy, cancers, malignancies, malignant tumor, malignant tumors, hematological malignancy, hematologic malignancies, hematological tumor, haematological malignancy, hematological malignancies
Treatment Gemcitabine, bevacizumab, Nab-paclitaxel, FOLFIRI, venetoclax, ABBV-621
Clinical Study IdentifierNCT03082209
SponsorAbbVie
Last Modified on27 October 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note